Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
By the use of genomic signatures to predict chemotherapeutic responsiveness in malignant brain tumors in order to conduct rationally designed clinical trials that select patients most likely to respond to standard and novel anti-tumor agents. These studies will facilitate the realization of “personalized medicine” approaches for the treatment of malignant brain tumors.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi